Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · IEX Real-Time Price · USD
6.29
-0.06 (-0.94%)
At close: Jun 17, 2024, 4:00 PM
6.28
-0.01 (-0.16%)
After-hours: Jun 17, 2024, 5:31 PM EDT
Ardelyx Revenue
Ardelyx had revenue of $159.11M in the twelve months ending March 31, 2024, with 152.32% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $46.02M with 304.81% year-over-year growth. In the year 2023, Ardelyx had annual revenue of $124.46M with 138.61% growth.
Revenue (ttm)
$159.11M
Revenue Growth
+152.32%
P/S Ratio
9.35
Revenue / Employee
$595,918
Employees
267
Market Cap
1.47B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
Dec 31, 2017 | 42.00M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
Dec 31, 2012 | 5.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.25B |
Tilray Brands | 743.25M |
U.S. Physical Therapy | 611.97M |
Supernus Pharmaceuticals | 597.40M |
Alphatec Holdings | 511.63M |
Dynavax Technologies | 236.15M |
Schrödinger | 188.48M |
Ligand Pharmaceuticals | 118.31M |
ARDX News
- 18 days ago - Ardelyx, Inc. Reports Employment Inducement Grants - GlobeNewsWire
- 26 days ago - Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 27 days ago - Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults - GlobeNewsWire
- 4 weeks ago - Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor) - GlobeNewsWire
- 5 weeks ago - Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference - GlobeNewsWire
- 6 weeks ago - Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings - GlobeNewsWire
- 3 months ago - Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy - GlobeNewsWire